The study for the efficacy of the combine therapy with proton pump inhibitor and rebamipide for the post-endoscopic submucosal dissection (ESD) gastric ulcer
Not Applicable
Recruiting
- Conditions
- gastric ulcer
- Registration Number
- JPRN-UMIN000007435
- Lead Sponsor
- Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Pregnant, possible pregnant, breast-feeding women (2) Patients with allergy for the test drugs (3) Patients with serious complications (4) Patients who are taking NSAIDs including COX-2 selective inhibitors, low dose aspirin and steroids (5) When gastric neoplasms are resected in a piecemeal fashion (6) When further treatment such as second ESD or surgery is required after the first ESD
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cure rates of gastric ulcer at 4 and 8 weeks of the treatment
- Secondary Outcome Measures
Name Time Method safety, influence of CYP2C19 genetic polymorphism, incidence of metachronous gastric cancer